SHANGHAI, CHINA,January2, 2024-JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development a...
17Interim Report 2023 JW (Cayman) Therapeutics Co. Ltd Management Discussion and Analysis In October 2022, we established a strategic alliance with 2seventy bio to develop and commercialize a cell therapy product directed to MAGE-A4 (including any mutations, fragments, modifications or derivatives...
2126 | Complete JW (Cayman) Therapeutics Co. Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell... Jan 02, 2024, 07:15 ET JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy JW Therapeutics (HKEx: ...
藥明巨諾宣佈與 2seventy bio達成獨家戰略合作,開發自身免疫疾病CAR-T治療產品 上海2024年1月2日 /美通社/ -- 藥明巨諾(港交所代碼:2126),一家獨立的、專注於研發、生產及商業化細胞免疫治療產品的創新型生物科技公司,於2024年1月2日宣佈與2seventy b... ...
SHANGHAI, CHINA,January2, 2024-JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development ...
“The true patient benefit of this collaboration lies in the ability to establish additional capabilities to rapidly test, learn and progress our innovative cell therapy programs,” said Steve Bernstein, chief medical officer, 2seventy bio. “...
2126 | Complete JW (Cayman) Therapeutics Co. Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.